2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z

Abstract Number: 146

Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
Abstract Number: 143

Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
Abstract Number: 173

Impact of a Nutrition-Focused Quality Improvement Intervention on Hospital Readmission Rates in Henoch-Schönlein Purpura with Gastrointestinal Involvement
Abstract Number: 161

Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States
Abstract Number: 176

Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 003

Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Abstract Number: 004

Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort
Abstract Number: 102

Implications of Positive Tests for ANCA in a Pediatric Population
Abstract Number: 172

Improved Self-efficacy and Knowledge in Pediatric Rheumatology Among General Pediatric Residents Following the Introduction of a Standardized Teaching Series
Abstract Number: 174

Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients
Abstract Number: 037

Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Abstract Number: 008

Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Abstract Number: 109

Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 006

Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Abstract Number: 189

Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic
Abstract Number: 180

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
Abstract Number: 159

Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis
Abstract Number: 062

Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study

Jump to: View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].